细胞毒性T淋巴细胞治疗人巨细胞病毒感染在造血干细胞移植中的应用

发布时间：2018-03-23 08:12

本文选题：造血干细胞移植　切入点：人巨细胞病毒　出处：《中国实验血液学杂志》2016年02期 　论文类型：期刊论文

【摘要】：人巨细胞病毒(human cytomegalovirus,HCMV)感染是造血干细胞移植后的常见并发症,是造成移植后患者死亡的主要原因之一。细胞毒性T淋巴细胞(cytotoxic T lymphocytes,CTL)是控制HCMV感染的重要免疫细胞,过继输注病毒特异性CTL对预防及治疗HCMV感染均安全有效。目前针对HCMV特异性CTL的制备方法仍在探索中。利用抗原递呈细胞刺激外周血单个核细胞(peripheral blood mononuclear cells,PBMC)制备CTL的方法操作简单,易于开展大规模临床实验;利用肽特异性四聚体或病毒特异性γ-干扰素抗体直接从供者PBMC筛选CTL的方法需要大量的供者外周血,且制备成本高;第三方CTL作为一种产品可以随时使用,但仍需解决HLA不相合的问题。另外,不同方法的临床疗效及安全性也存在差异。本文对目前采用的制备HCMV特异性T淋巴细胞的方法及其疗效进行综述。
[Abstract]:Human cytomegalovirus (HCMV) infection is a common complication after hematopoietic stem cell transplantation and one of the main causes of death after transplantation. Cytotoxic T lymphocyte (CTL) is an important immune cell to control HCMV infection. Adoptive infusion of virus-specific CTL is safe and effective in the prevention and treatment of HCMV infection. At present, the preparation of HCMV specific CTL is still in the process of being explored. The preparation of CTL from peripheral blood mononuclear cells stimulated by antigen-presenting cells and peripheral blood mononuclear cells. The method is simple to operate, The method of screening CTL from donor PBMC directly by using peptide specific tetramer or virus specific interferon antibody requires a large number of donor peripheral blood, and the preparation cost is high. Third party CTL as a product can be used at any time, but still need to solve the problem of inconsistent HLA. The clinical efficacy and safety of different methods are also different. In this review, the methods and efficacy of HCMV specific T lymphocytes preparation are reviewed.
【作者单位】：军事医学科学院附属医院造血干细胞移植科;全军造血干细胞研究所;
【基金】：解放军307医院创新基金资助
【分类号】：R457.7

【相似文献】